Scinovex
review Open Access

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

Cochrane Database of Systematic Reviews · 2002 · pp. CD001447–CD001447
R G MillerJD MitchellMary LyonDH Moore

Abstract

Riluzole 100 mg daily is reasonably safe and probably prolongs survival by about two months in patients with amyotrophic lateral sclerosis. More studies are needed, especially to clarify its effect in older patients (over 75 years), and those with more advanced disease.

Amyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders ResearchSynthetic Organic Chemistry MethodsRiluzoleAmyotrophic lateral sclerosisMedicinePlaceboHazard ratioAdverse effectClinical trialRandomized controlled trialInternal medicineDisease

MeSH terms

Amyotrophic Lateral SclerosisHumansExcitatory Amino Acid AntagonistsRiluzole
Citations
910
FWCI
field-weighted impact
References
48
Percentile
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.